Larry Yost from The Atticus Group is a co-author on a new peer-reviewed paper published in Biomarker Insights. The paper, entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro diagnostic test for the determination of miR-31-3p expression levels in formalin-fixed paraffin-embedded (FFPE) metastatic colorectal cancer tumor specimens” reviews the analytical sensitivity and specificity, robustness, reproducibility, repeatability and accuracy of a proprietary test for the novel mircroRNA biomarker, miR-31-3p, under a number of testing conditions using several differing testing platforms. The data from these studies confirms the ability of the testing method to provide an analytically precise assay for the clinical measurement of miR-31-3p from FFPE tumor samples in patients with metastatic colorectal cancer. Click here to view full publication.
Contact us to learn about The Atticus Group can support companies in the development and implementation of their publication strategies or to learn more about how we can help your needs.
